Vanguard Fiduciary Trust
HRTX icon

Vanguard Fiduciary Trust’s Heron Therapeutics HRTX Stock Holding History

Vanguard Fiduciary Trust’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$583K Buy
1,365,119
+212,405
+18% +$170K ﹤0.01% 3224
2026
Q1 		$922K Buy
+1,152,714
New +$1.34M ﹤0.01% 2955

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Vanguard Fiduciary Trust's HRTX Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Heron Therapeutics (HRTX) stake by 18% in Q2 2026, buying an estimated $170K and bringing the position to 1,365,119 shares worth $583K. The position accounts for ﹤0.01% of the portfolio, ranked #3224.

Vanguard Fiduciary Trust first reported a position in HRTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $922K in Q1 2026. 161 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Vanguard Fiduciary Trust held 1,365,119 shares of Heron Therapeutics worth $583K as of Q2 2026.
  • Vanguard Fiduciary Trust bought 212,405 Heron Therapeutics shares in Q2 2026, an estimated $170K.
  • Heron Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3224 holding.
  • Vanguard Fiduciary Trust first reported a position in Heron Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Heron Therapeutics position peaked at $922K in Q1 2026.
  • 161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.